BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30224273)

  • 21. Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
    Batirel HF; Metintas M; Caglar HB; Ak G; Yumuk PF; Ahiskali R; Bozkurtlar E; Bekiroglu N; Lacin T; Yildizeli B; Yuksel M
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2724-2733. PubMed ID: 29510939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducibility of histological subtyping of malignant pleural mesothelioma.
    Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
    Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
    Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
    Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Richards WG; Sugarbaker DJ
    Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
    Barsky AR; Ahern CA; Venigalla S; Verma V; Anstadt EJ; Wright CM; Ludmir EB; Berlind CG; Lindsay WD; Grover S; Cengel KA; Simone CB
    Clin Lung Cancer; 2020 Nov; 21(6):e583-e591. PubMed ID: 32611504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Malignant Pleural Mesothelioma in the Elderly Population.
    Verma V; Wegner RE; Ludmir EB; Hasan S; Colonias A; Grover S; Friedberg JS; Simone CB
    Ann Surg Oncol; 2019 Aug; 26(8):2357-2366. PubMed ID: 31011908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
    Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
    Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
    Hasegawa S; Kondo N; Matsumoto S; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Kamikonya N; Tsujimura T; Nakano T
    Semin Thorac Cardiovasc Surg; 2019; 31(2):301-309. PubMed ID: 30639549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
    Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
    JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgery in Malignant Pleural Mesothelioma.
    Bueno R; Opitz I;
    J Thorac Oncol; 2018 Nov; 13(11):1638-1654. PubMed ID: 30121394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.
    Verma V; Wegner RE; Adeberg S; Horne ZD; Grover S; Friedberg JS; Simone CB
    Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):1125-1132. PubMed ID: 31226401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.